Insmed to Present at TD Cowen & Leerink Healthcare Conferences – 2026
- – February 13, 2026 – Insmed Incorporated (Nasdaq: INSM) announced today that its management team will participate in two investor conferences in March, providing updates on the biopharmaceutical...
- The company will first present at the March 2, 2026, 46th Annual TD Cowen Healthcare Conference in Boston, Massachusetts, at 9:50 a.m.
- Both presentations will be webcast live and subsequently archived for 30 days on the investor relations section of Insmed’s website, www.insmed.com.
BRIDGEWATER, N.J. – – Insmed Incorporated (Nasdaq: INSM) announced today that its management team will participate in two investor conferences in March, providing updates on the biopharmaceutical company’s progress, and outlook.
The company will first present at the , 46th Annual TD Cowen Healthcare Conference in Boston, Massachusetts, at . Insmed will then participate in the Leerink Partners Global Healthcare Conference in Miami, Florida, on , beginning at .
Both presentations will be webcast live and subsequently archived for 30 days on the investor relations section of Insmed’s website, www.insmed.com. This accessibility allows a broader audience, including investors and analysts unable to attend in person, to stay informed about the company’s developments.
Insmed, which describes itself as a “people-first global biopharmaceutical company,” is focused on developing therapies for serious diseases. The company currently markets two approved therapies for chronic, debilitating lung diseases and is actively pursuing a diverse pipeline of investigational medicines. Its research programs span a range of advanced technologies, including gene therapy, artificial intelligence-driven protein engineering, and RNA end-joining.
The company’s commitment to innovation extends beyond its scientific pursuits. Insmed has been recognized as a top employer in the biopharmaceutical industry for five consecutive years, earning the distinction of being the No. 1 Science Top Employer. This recognition underscores the company’s focus on attracting and retaining talent, which is crucial for driving its research and development efforts.
Insmed’s participation in these investor conferences comes as the biopharmaceutical sector continues to face both opportunities and challenges. The demand for novel therapies remains high, particularly in areas like pulmonary and inflammatory conditions, where significant unmet medical needs persist. However, the industry is also navigating a complex landscape of pricing pressures, regulatory scrutiny, and evolving reimbursement models.
The TD Cowen Healthcare Conference and the Leerink Partners Global Healthcare Conference are both prominent events on the investor calendar, attracting a wide range of participants from the healthcare ecosystem. These conferences provide a platform for companies like Insmed to engage with investors, analysts, and other stakeholders, and to share their vision for the future.
Insmed’s presence at these events signals its continued commitment to transparency and investor engagement. By providing regular updates on its progress, the company aims to build confidence among its shareholders and attract new investment. The webcasts will allow for broad dissemination of information, ensuring that interested parties can access the presentations regardless of their location.
Investors interested in accessing the webcasts and learning more about Insmed can visit the company’s investor relations website at www.insmed.com. Further information about the conferences themselves can be found on the respective event websites.
Investor and Media Contacts:
- Bryan Dunn, Vice President, Investor Relations, [email protected], (646) 812-4030
- Claire Mulhearn, Vice President, Corporate Communications, [email protected], (862) 842-6819